Advertisement

Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4320 | Ordered by Date (descending)
1 2 3 ... 42 43 44  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cellbox Solutions–EU (govt): investment, 2024– equity investment up to €10m from EIC Accelerator 2024-01-01
Eligo Bioscience–SEVERAL: investment, 202312 financing round Series B $30m led by Sanofi Ventures 2023-12-05
Carmot Therapeutics–Roche: investment, 202312– acquisition $2.7b upfront + $400m milestones by Roche 2023-12-04
Evomedis–MC Services: public relations, 202311 service existent by MC Services 2023-11-23
T3 Pharmaceuticals–Boehringer: investment, 202311 acquisition of T3 Pharma for up to CHF430m by Boehringer Ingelheim 2023-11-22
Evolva–Lallemand: investment, 202311– acquisitions of operations via 100% of Evolva AG for CHF20m + CHF10m milestones by Danstar Ferment AG 2023-11-21
RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF 2023-11-21
RED Horticulture–SEVERAL: investment, 202311 financing round Series A €17m led by ECBF with Demeter IM + Unigrains 2023-11-21
Roche–Nvidia: AI-based drug r+d, 202311– collab strategic alliance multi-year of Genentech with Nvidia using Nvidia DGX Cloud + Nvidia BioNemo 2023-11-21
NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital 2023-11-15
Glox Therapeutics–SEVERAL: investment, 202311 seed financing round £4.3m led by BIVF + Scottish Enterprise 2023-11-14
Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures 2023-11-14
Insempra–Germany (govt): grant, 202311–202610 innvoation grant €1.5m from SPRIND to advance BioTreasure prototype 2023-11-10
Valanx Biotech–Niederösterreich (govt): investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor TE 2023-11-07
Valanx Biotech–SEVERAL: investment, 202311 growth financing round €2.3m incl equity + public funding led by SkyGene 2023-11-07
Valanx Biotech–SkyGene: investment, 202311 growth financing round totalling €2.3m in equity + public funding incl new + lead investor SkyGene 2023-11-07
Valanx Biotech–SOSV: investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor SOSV 2023-11-07
Valanx Biotech–Xista Science Ventures: investment, 202311 growth financing round totalling €2.3m equity + public funding incl existing investor Xista 2023-11-07
HeartBeat.bio–SEVERAL: investment, 202311 financing round pre-Series A €4.5m with i&i Biotech Fund + Invest AG + aws + Tensor Ventures 2023-11-02
Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV 2023-11-02
Cambrium–Essential Capital: investment, 202311 seed financing round totalling €8m incl lead investor Essential Capital 2023-11-01
Cambrium–Hof Capital: investment, 202311 seed financing round totalling €8m incl co-investor Hof Capital 2023-11-01
Cambrium–Merantix: investment, 202311 existing investor Merantix with approx €3m invested? 2023-11-01
Cambrium–SEVERAL: investment, 202311 seed financing round €8m led by Essential Capital 2023-11-01
Cambrium–SNR: investment, 202311 seed financing round totalling €8m incl co-investor SNR 2023-11-01
Cambrium–Valor Equity Partners: investment, 202311 seed financing round totalling €8m incl co-investor Valor Equity Partners 2023-11-01
LimFlow–Inari Medical: investment, 202311– acquisition $250m cash upfront at closing + $165m by Inari Medical 2023-11-01
MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets 2023-10-30
Merck (DE)–Hengrui: cancer drugs, 202310– strategic alliance €160m upfront + total up to €1.4b license HRS-1167 + option SHR-A1904 ww excl China 2023-10-30
CMBlu Energy–STRABAG: investment, 202310 equity investment €100m in connection with preferred partnership agreement 2023-10-23
FarmInsect–Bavaria (govt): investment, 202310 financing round Series A totalling €8m incl existing + co-investor Bayern Kapital 2023-10-23
FarmInsect–EU (govt): investment, 202310 financing round Series A totalling €8m incl new + co-investor EIC Fund 2023-10-23
FarmInsect–High-Tech Gründerfonds: investment, 202310 financing round Series A totalling €8m incl existing + co-investor HTGF 2023-10-23
FarmInsect–Minderoo Foundation: investment, 202310 financing round Series A totalling €8m incl new + co-investor MF Strategic Impact Fund 2023-10-23
FarmInsect–Sandwater: investment, 202310 financing round Series A totalling €8m incl new + lead investor Sandwater 2023-10-23
FarmInsect–SEVERAL: investment, 202310 financing round Series A €8m led by Sandwater 2023-10-23
FarmInsect–TU Munich: investment, 202310 financing round Series A totalling €8m incl existing + co-investor UnternehmerTUM Funding for Innovators 2023-10-23
STRABAG––CMBlu Energy: energy storage solutions, 202310– strategic collab preferred supplier agreement for SolidFlow batteries 2023-10-23
Biotech Austria–MC Services: public relations, 202310 service existent by MC Services 2023-10-17
BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC 2023-10-12
Japan Tobacco–Max Planck: drug discovery, 202310– collab up to 7 years with Lead Discovery Center + its academic network 2023-10-11
AstronauTx–SEVERAL: investment, 202310 financing round Series A ¯£48m led by Novartis Venture Fund 2023-10-09
LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund 2023-10-09
United Kingdom (govt)–Siemens: PET/CT scanner, 202310–202304 supply 2 Biograph Vision Quadra PET/CT scanners by Siemens Healthineers to NPIP 2023-10-05
MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker 2023-10-04
Orakl Oncology–SEVERAL: investment, 202310 financing round €3m led by Speedinvest with HCVC + Verve Ventures 2023-10-04
Point Biopharma–Lilly: investment, 202310– cash tender offer $1.4b by Lilly at $12.5/share 2023-10-03
Kranus Health–A Round Capital: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor A Round 2023-10-02
Kranus Health–CSS (CH): investment, 202310 financing round Series A expansion totalling approx $8.5m incl new + co-lead investor SwissHealth Ventures 2023-10-02
Kranus Health–High-Tech Gründerfonds: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor HTGF 2023-10-02
Kranus Health–Karista: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-lead investor Karista 2023-10-02
Kranus Health–SEVERAL: investment, 202310 financing round Series A expansion approx $8.5m bringing total Series A to $15m 2023-10-02
Kranus Health–Wenvest: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor Wenvest 2023-10-02
Refeyn–Alto Marketing: public relations, 202310 service existent by Alto Marketing Ltd 2023-10-02
MetrioPharm–SEVERAL: investment, 202310c financing round Series D 1st closing CHF18m 2023-10-01
Alentis Therapeutics–Kyan Technologies: drug discovery technology, 202309– collab using Optim.AI + PD3D technologies for Claudin-1 expression research 2023-09-29
Nagi Bioscience–Excellis: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-investor Excellis Holding 2023-09-28
Nagi Bioscience–imec: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor imec.xpand 2023-09-28
Nagi Bioscience–SEVERAL: investment, 202309 financing round Series A CHF12.4m co-led by Swisscanto + imec.xpand 2023-09-28
Nagi Bioscience–Verve Capital Partners: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor Verve Ventures 2023-09-28
Nagi Bioscience–Zürcher Kantonalbank: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor ZKB 2023-09-28
Nagi Bioscience–Zürcher Kantonalbank: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor Swisscanto 2023-09-28
4SC–Optimum Strategic Communications: public relations, 202309 service existent by Optimum 2023-09-27
Kern Tec–EU (govt): investment, 202309 financing round Series A totalling €12m incl co-investor EIC Fund 2023-09-27
Kern Tec–PeakBridge: investment, 202309 financing round Series A totalling €12m incl co-investor PeakBridge Growth 2 fund 2023-09-27
Kern Tec–SEVERAL: investment, 202309 financing round Series A €12m led by Telos Impact (eventually total includes grants?) 2023-09-27
Kern Tec–Telos Impact: investment, 202309 financing round Series A totalling €12m incl lead investor Telos Impact 2023-09-27
Co.faktor–Cytel: investment, 202309 acquisition of Co.faktor GmbH by Cytel Inc 2023-09-26
Cytel–BioStrata: public relations, 202309 service existent by BioStrata 2023-09-26
Pepceuticals–Biosynth: investment, 202309 acquisition of Pepceuticals Ltd by Biosynth 2023-09-25
Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202309–203309 supply 10y >$100m of nca lutetium-177 to Point Biopharma 2023-09-25
Traceless Materials–b.value: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor b.value 2023-09-25
Traceless Materials–GLS Bank: investment, 202309 financing round Series A totalling €36.6m incl new + co-investor GLS Bank Hamburg 2023-09-25
Traceless Materials–High-Tech Gründerfonds: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor HTGF 2023-09-25
Traceless Materials–Planet A: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor Planet A Ventures 2023-09-25
Traceless Materials–SEVERAL: investment, 202309 financing round Series A €36.6m led by UB FIGG plus other new + all existing investors 2023-09-25
Traceless Materials–Sparkassen (DE): investment, 202309 financing round Series A totalling €36.6m incl new + co-investor HaSpa 2023-09-25
Traceless Materials–SWEN Capital Partners: investment, 202309 financing round Series A totalling €36.6m incl new + co-lead investor Blue Ocean fund 2023-09-25
Traceless Materials–United Bankers: investment, 202309 financing round Series A totalling €36.6m incl new + lead investor UB FIGG 2023-09-25
CARTemis Therapeutics–Germany (govt): grant, 202309c– BMBF grant €1.3m for clinical trials with CAR T-cell therapy targeting BCMA 2023-09-21
CARTemis Therapeutics–Helmholtz: investment, 202309 existent financing from Helmholtz Association spin-off fund 2023-09-21
Mainz Biomed–MC Services: public relations, 202309 service existent by MC Services 2023-09-20
Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront 2023-09-20
Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties 2023-09-20
Broken String Biosciences–Holtzbrinck: investment, 202309 financing round Series A totalling $15m incl existing + co-investor DvH Ventures 2023-09-18
Broken String Biosciences–SEVERAL: investment, 202309 financing round Series A $15m co-led by Illumina Ventures + Mérieux Equity Partners 2023-09-18
SHS Capital–SEVERAL: investment, 202309 final closing of SHS VI fund adding ca €50 after first close bringing total fund size to €270m 2023-09-13
Moderna–Immatics: cancer drugs, 202309– strategic r+d collab $120m upfront + >$1.7b funding + milestones + royalties combing tech platforms 2023-09-11
Grande Bio-tech–Oncgnostics: molecular diagnostics, 202309 – distribution of early cancer detection tests developed by Oncgnostics in ASEAN countries 2023-09-05
Oncgnostics–Grande Bio-tech: investment, 202309 financing round totalling €7-digit incl lead investor Grande Bio-tech Co Ltd with €7-digit investment 2023-09-05
Oncgnostics–High-Tech Gründerfonds: investment, 202309 financing round totalling €7-digit incl existing + co-investor HTGF 2023-09-05
Oncgnostics–SEVERAL: investment, 202309 financing round €7-digit led by Grande Bio-tech Co Ltd + incl bm-t + HTGF 2023-09-05
Oncgnostics–Thuringia (govt): investment, 202309 financing round totalling €7-digit incl existing + co-investor bm-t 2023-09-05
Takara Shuzo–Eppendorf: lab automation equipment, 202308– collab strategic co-marketing agreem automating Takara Bio chemistries on epMotion platforms 2023-08-25
PhenomeX–Bruker: investment, 202308–202310 acquisition cash tender offer $108m by Bruker at $1/share 2023-08-17
Bactolife–SEVERAL: investment, 202308 financing round Series A €30m led by Athos + incl Gates Foundation + Novo Holdings et al 2023-08-08
IO Biotech–SEVERAL: investment, 202308 private placement $75m with existing + new investors 2023-08-07
AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany 2023-08-02
Bind-X–Greeneering Invest: investment, 202308 financing round Series B totalling €10m incl new investor Greeneering Invest 2023-08-01
Bind-X–Heritage Group: investment, 202308 financing round Series B totalling €10m incl new investor HG Ventures 2023-08-01
1 2 3 ... 42 43 44  next pagenext page



Advertisement

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top